Yes that matches my understanding. As to where the cells are actually being harvested and expanded, I have no idea.
Agreed that they are using Tigenix's adipose MSC's rather than Mesoblast's bone marrow sourced MSC's for this trial. I did read a paper the other day that compared immunomodulatory responses for MSC's derived from different tissue sources and as I recall both adipose and bone marrow derived cells worked well
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-504
-
- There are more pages in this discussion • 344 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
0.015(1.62%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 95.0¢ | 93.5¢ | $161.1K | 170.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 118650 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 4442 | 4 |
View Market Depth
| Last trade - 10.05am 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |